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DOI 10.1186/s12891-015-0574-6RESEARCH ARTICLE Open AccessAugmentation of tibial plateau fractures with
an injectable bone substitute: CERAMENT™.
Three year follow-up from a prospective study
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Background: Reduction of tibial plateau fractures and maintain a level of well aligned congruent joint is key to
a satisfactory clinical outcome and is important for the return to pre-trauma level of activity. Stable internal fixation
support early mobility and weight bearing. The augmentation with bone graft substitute is often required to support
the fixation to mantain reduction. For these reasons there has been development of novel bone graft substitutes for
trauma applications and in particular synthetic materials based on calcium phosphates and/or apatite combined with
calcium sulfates. Injectable bone substitutes can optimize the filling of irregular bone defects. The purpose of this study
was to assess the potential of a novel injectable bone substitute CERAMENT™|BONE VOID FILLER in supporting the
initial reduction and preserving alignment of the joint surface until fracture healing.
Methods: From June 2010 through May 2011 adult patients presenting with acute, closed and unstable tibial plateau
fractures which required both grafting and internal fixation, were included in a prospective study with percutaneous or
open reduction and internal fixation (ORIF) augmented with an injectable ceramic biphasic bone substitute
CERAMENT™|BONE VOID FILLER (BONESUPPORT™, Lund, Sweden) to fill residual voids. Clinical follow up was performed
at 1, 3, 9 and 12 months and any subsequent year; including radiographic analysis and Rasmussen system for knee
functional grading.
Results: Twenty four patients, balanced male-to-female, with a mean age of 47 years, were included and followed
with an average of 44 months (range 41–52 months). Both Schatzker and Müller classifications were used and was type
II or 41-B3 in 7 patients, type III or 41-B2 in 12 patients, type IV or 41-C1 in 2 patients and type VI or 41-C3 in 3 patients,
respectively. The joint alignement was satisfactory and manteined within a range of 2 mm, with an average of
1.18 mm. The mean Rasmussen knee function score was 26.5, with 14 patients having an excellent result and the
remaining 10 with a good result.
Conclusion: It can be concluded that radiological and clinical outcome was satisfactory and obtained in all cases
without complications. This injectable novel biphasic hydroxyapatite and calcium sulfate ceramic material is a valuable
armamentarium in the treatment of trauma where bone graft is required.
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Table 1 Demographics, Schatzker and Müller classifications and
type of fixation
Age (years) Mean 47 (range 32–64)
Male gender 50 %
Schatzker
classification
N = 7 II; N = 12 III; N = 2 IV; N = 3 VI
Müller classification N = 12 41-B2; N = 7 41-B3; N = 2 41-C1; N = 3 41-C3
Screw fixation 15 pts
Plate fixation 9 pts
pts, patients
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The goal of tibial plateau fracture management is a stable,
well aligned, congruent joint, with a painless range of mo-
tion and function [1]. In the analysis of the treatment of
60 patients with tibial plateau fractures Blokker et al. [2]
concluded that the single most important factor in pre-
dicting outcome was the fracture reduction. Open reduc-
tion and internal fixation (ORIF) with standard plates and
screws or screws alone does not always mantain the
reduction [3, 4]. After restoration of a congruent joint sur-
face bone grafting and buttress plating are often needed to
allow early mobility and weight bearing [1].
Bone grafting is thus often needed following reduction
of the tibial fracture to fill residual metaphyseal voids
and gaps. Autograft is considered ideal for grafting pro-
cedures, providing osteoinductive growth factors, osteo-
genic cells being an osteoconductive scaffold [5] but is
associated with morbidity at the donor site and is limited
in supply. Allograft has been employed as a good alter-
native to autograft in the treatment of depressed tibial
fractures [6] but the logistics of supply and the concern
of potential disease transmission remains [7]. Synthetic
bone graft substitutes have been gaining popularity as
viable alternatives for void and defect filling eliminating
the concerns with autograft and allograft. These synthetic
bone substitutes have invariably been based on calcium
phosphate and/or calcium sulfate materials which are
osteoconductive and facilitate bone remodeling.
We present here the three year radiological and func-
tional results of a prospective series of tibial plateau frac-
tures treated with closed or open reduction, internal
fixation and augmentation with an injectable novel hy-
droxyapatite and calcium sulfate bi-phasic ceramic bone
substitute, CERAMENT™.
Methods
During 12 months from June 2010 through May 2011
adult patients between 18 and 70 years, presenting with
acute, closed and unstable proximal tibial fractures
which required both grafting and internal fixation, were
included in a prospective study with percutaneous or
open reduction and internal fixation (ORIF) augmented
with an injectable ceramic biphasic bone substitute CER-
AMENT™|BONE VOID FILLER (BONESUPPORT™,
Lund, Sweden) to fill residual gaps. Excluded from the
study were patients with metabolic bone disease, type 1
diabetes or uncontrolled type 2 diabetes, malignancy or
on treatment with systemic steroids or immunosuppres-
sive therapy, infection at the operative site, concurrent
treatment with other bone substitutes including auto-
graft, peripheral vascular disease, alcoholism, substance
abuse, correlated peripheral nerve damage, pregnancy or
breast feeding or fertile women not on routine contra-
ceptive control, a history of anaphylactic reaction toiodine-based radiocontrast agents, known bleeding dis-
orders, hyperthyreosis and thyroid adenoma. Tobacco
use was not an exclusion criteria. This investigation
was performed in accordance with the ethical standards
of the Declaration of Helsinky and all the patients gave
informed consent prior to being included in the study
but local ethics committee authorization was not re-
quired because the material was regarded to the stand-
ard of care.
The flowable and in situ curing bio-ceramic bone sub-
stitute was injected under fluoroscopy with a minimally
invasive technique from the contralateral side of the
fractured tibia via the bony window used for reduction
(all patients of Schatzker type II or Müller 41-B3 and 8
patients out of type III or 41-B2) and internal fixation
was applied. The material consists of highly osteocon-
ductive hydroxyapatite particles embedded in a calcium
sulphate (CaS) paste, which is prepared 3 minutes before
application by mixing with the water-soluble radiocon-
trast agent, iohexol, in a closed system. Once implanted,
CERAMENT™ has a compressive strength of at least
5 MPa, which is comparable to that of healthy trabecular
cancellous bone. Due to its similarity to endogenous bone,
the CERAMENT™ implant triggers an endogenous pre-
cipitation of hydroxyapatite on its surface which prevents
passive resorption. The sulphate dehydrate part of the im-
plant is gradually resorbed during 7–8 weeks and being
replaced by ingrowing bone that remodels to form tra-
becular bone, supplied by the remaing hydroxyapatite
nanoparticles thus incorporated in to the newly formed
trabecular bone [8]. Progressive load bearing was allowed
after 2 weeks for Schatzker II and III or Müller AO type
41-B fractures and after 4 weeks for type IV and VI or type
41-C fractures.
Clinical follow up was performed at 1, 3, 9 and
12 months and any subsequent year; including radio-
graphic analysis and knee functional grading. X-ray re-
view allowed the assessment of osteosynthesis stability,
preserved alignment of the joint surface following reduc-
tion, bone substitute resorption and fracture healing.
The Rasmussen system [9] was employed for knee func-
tional grading. A CT scan was taken preoperatively to
Table 2 Post-operative radiographic assessment
Reduction: overall mean step-off Patients Mean step-off Schatzker classification Müller classification
1.18 mm 16 ≤1.2 mm N = 4 II; N = 12 III N = 12 41-B2; N = 4 41-B3
5 1.2≤ 1.5 mm N = 3 II; N = 2 VI N = 3 41-B3; N = 2 41-C3
2 1.6 mm N = 2 IV N = 2 41-C1
1 ≈1.7 mm N = 1 VI N = 1 41-C3
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fracture classifications according to Schatzker [10] and
Müller [11].
Results
Ninety-three consecutive patients with a tibial plateau
fracture presented at the Emergency Department of the
University Hospital “Tor Vergata” over the 12 month re-
cruitment period. A total of 24 patients, 12 males and 12
females, met the inclusion criteria and were included
and treated by three of the authors: the patients ranged
from 32 to 64 years, mean 47 years. Schatzker classifica-
tions were type II (7 patients), type III (12 patients), type
IV (2 patients) and type VI (3 patients); Müller classifica-
tions were as follows: 41-B2 (12 patients), 41-B3 (7 pa-
tients), 41-C1 (2 patients) and 41-C3 (3 patients). Fifteen
patients (all type II or 41-B3 and 8 patients out of type
III or 41-B2) were operated with two percutaneous can-
nulated screws which were inserted through the lateral
side after that a distal medial window to reduce the frac-
ture first and to introduce the bone substitute later, was
performed; the remaining 9 patients (4 patients out of
type III or 41-B2, all type IV or 41-C1 and all type VI or
41-C3) needed an angled stable sliding plate with screws
and the bone substitute was inserted directly by the
lateral approach.
The interim follow-up period was an average of
44 months (41–52 months) as presented in Table 1.
Radiographic analysis demonstrated that a loss of frac-
ture reduction was maintained within the satisfactory
range of 2 mm, with an average of 1.18 mm as presentedFig. 1 A 35 year old female with a Schatzker II, Müller AO grade 41-B3 fractur
CERAMENT™ was injected under fluoroscopy following closed reduction andin Table 2. The CERAMENT™ resorption was complete
in all cases after an average of 5 months (3–8 months).
The mean Rasmussen knee function score was 26.5,
with 14 patients exhibiting an excellent result and the
remaining 10 with a good rating. A case of a 35 year old
female with a Schatzker II, Müller AO grade 41-B3 frac-
ture, is presented in Figs. 1, 2 and 3.
Discussion
Following reduction of tibial fractures bone graft is often
needed to fill residual voids and gaps. Autograft and
allograft have been used for this purpose but there exists
disadvantages that cannot be overlooked, for instance
donor site pain and morbidity, blood loss, infection, slow
rate of incorporation and secondary fractures. For these
reasons there has been an emergence of bone graft
substitutes for trauma applications and in particular
synthetic materials based on calcium phosphates and/or
apatite calcium sulfates. Synthetic bone substitutes pro-
vide a ready and plentiful supply of material and inject-
able versions optimize the filling of irregular bone
defects. Ozturkmen et al. [12] in the treatment of 28 pa-
tients with ORIF and a calcium phosphate based bone
cement found that the time to full weight bearing was
reduced to less than 6.5 weeks. In a clinical series of 43
patients with trauma fractures McAndrew et al. [13]
demonstrated the efficacy of a calcium phosphate based
bone substitute at a 6 to 12 month follow-up, with 90 %
in a fracture group and 85 % in a non-union group dem-
onstrating healing. A meta-analysis of randomized clin-
ical trials conducted by Bajammal et al. [14] in a seriese. (a) Pre-operative X-rays; (b) Pre-operative CT-scan; (c) Intra-operatively
before fixation with two cannulated cancellous bone screws
Fig. 3 Excellent bone regeneration with the removal of the
hardware after 9 months since osteosynthesis
Fig. 2 X-rays follow-up at different steps. (a, b) The positioning of the bioceramic may been seen on the immediate post-operative frontal and
sagittal x-rays; (c) On the same views at 1 month post-op there is no further evidence of radiocontrast of the bone cement indicating the
washout of iohexol; (d) The remodeling process is now progressing. New bone appears well consolidated at 3 months
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neck, intertrochanteric femoral and calcaneal indica-
tions, concluded that loss of fracture reduction was less
with a calcium phosphate based bone filler in compari-
son with autogenous bone graft. Bucholz et al. [15]
found no significant differences in radiographic and clin-
ical assessments between a calcium phosphate based
bone cement and autograft for residual void and gap in
a series of 40 patients with displaced tibial fracture.
In cadaveric pre-clinical investigations [16–18] calcium
phosphate based cements used to fill proximal tibial de-
fects following trauma were found to be stronger than
autologous graft filling with greater stiffness, higher
fatigue strength and a greater ultimate load supporting
capacity. This is supported clinically by Simpson and
Keating [19] at 1 year in 26 patients in an equally bal-
anced study with the use of autograft and a calcium
phosphate based bone substitute for the treatment of
proximal tibial fractures. The mean residual plateau de-
pression was 4 mm in the autograft group (coupled with
buttress plating) and 0.7 mm in the calcium phosphate
based group (with minimal internal fixation) at 1 year
follow-up. They also were able to use less hardware with
the calcium phosphate group and had a corresponding
40 % reduction in operative time on average (from a
mean of 101 min to 55 min). Larsson and Hammick [20]
in their analysis of randomized clinical trauma studies
support the benefits of injectable calcium phosphate
based bone substitutes as suitable alternatives to auto-
graft, with the flexibility to be applied around the hard-
ware once in position and to augment weaker bone
around the screws as well as replace autograft in defects
and voids.
It can be concluded from our preliminary review that
radiological and clinical outcome was satisfactorily ob-
tained in all cases without complications. The enhanced
stability with the application of CERAMENT™ supported
and maintained fracture reduction with a mean setting
of 1.18 mm at an average of 9 months in the currentclinical series, well within the satisfactory range of 2 mm
and in line with the findings of Simpson and Keating
[19]. The Rasmussen knee functional score had all pa-
tients in the good and excellent categories demonstrat-
ing results at least as good as those for Ozturkmen et al.
[12] who employed calcium phosphate cement augmen-
tation in their treatment of depressed tibial fractures and
returned 78 % of patients back to their pre- operative
level of activity.
CERAMENT™ is designed to remodel in tune with the
natural bone remodelling process. Due to the microporos-
ity through the release of the CaS component, an immedi-
ate flow of tissue fluids with nutrients and growth factors
are allowed to penetrate the implant, which promotes
osteoclasts and macrophages to enter the material and
create macropores resulting in a widespread ingrowth of
early bone. The end result is full transformation and
remodeling into mature bone after 9–12 months [21, 22].
This interim study at an average of 44 months follow-up
of the bone remodeling process shows that new normal
bone is formed and maintained which is important for
clinical performance in the longer term.
This investigation has some limitations. The study
population is relatively small and doesn’t effectively
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of the authors performed the surgical procedures. Next,
a control group using other bone substitutes or grafting
was not enrolled. Lastly, patients were followed for a
mid-period, so further studies will be required to verify
the long-term clinical and radiological outcomes.
Conclusion
CERAMENT™|BONE VOID FILLER has demonstrated
that it is a viable replacement to bone grafting in filling
voids and gaps following fracture of the tibial plateau. It
provides a material, being injectable which optimizes the
filling of irregular bone defects. This study has demon-
strated that CERAMENT™ has supported the reduction
and preservation of alignment of the joint surface until
fracture healing. This makes the novel biphasic bio-
ceramic material an attractive solution in the treatment
of trauma situations where bone graft is required.
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